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Significance of this study
What is already known about this subject?
 ► Hepatic insulin clearance (HIC) was reported to de-
crease in patients with type 2 diabetes and metabolic 
syndrome; however, hyperglycemia was suggested 
to enhance HIC, and it is not known whether poorly 
controlled diabetes increases HIC in patients with 
type 2 diabetes.
What are the new findings?
 ► Hepatic insulin clearance was increased in patients 
with high glycated hemoglobin type 2 diabetes.
 ► Hepatic insulin clearance was increased in patients 
with low insulin secretion condition.
 ► Hepatic insulin clearance was increased in patients 
with low insulin resistance condition.
 ► Hepatic insulin clearance was increased in patients 
with high adiponectin condition.
How might these results change the focus of 
research or clinical practice?
 ► Postprandial insulin levels in patients with poorly 
controlled type 2 diabetes should be interpreted with 
caution.
 ► We suggest that postprandial C- peptide levels 
should be measured in patients with poorly con-
trolled type 2 diabetes to determine their ability to 
secrete insulin.
AbStrAct
Introduction Hepatic insulin clearance (HIC) is an 
important pathophysiology of type 2 diabetes. HIC was 
reported to decrease in patients with type 2 diabetes 
and metabolic syndrome. However, hyperglycemia was 
suggested to enhance HIC, and it is not known whether 
poorly controlled diabetes increases HIC in patients 
with type 2 diabetes. We investigated whether HIC was 
increased in patients with poorly controlled diabetes, and 
whether HIC was associated with insulin resistance and 
incretins.
Research design and methods We performed a meal 
tolerance test and the hyperinsulinemic–euglycemic 
clamp in 21 patients with type 2 diabetes. We calculated 
the postprandial C- peptide area under the curve (AUC)- 
to- insulin AUC ratio as the HIC; measured fasting and 
postprandial glucagon- like peptide-1 (GLP-1), glucose- 
dependent insulinotropic polypeptide (GIP) and glucagon 
levels and analyzed serum adiponectin and zinc 
transporter-8 (ZnT8) gene polymorphism.
Results The HIC significantly correlated with glycated 
hemoglobin (HbA1c) (r_S=0.58, p<0.01). In patients 
with high HIC above the median of 6.5, the mean HbA1c 
was significantly higher compared with low HIC below 
the median. Homeostatic model assessment (HOMA)- 
beta (r_S=−0.77, p<0.01) and HOMA- IR (r_S=−0.66, 
p<0.005) were correlated with HIC. The M/I value in the 
clamp study was correlated with HIC. GLP-1- AUC and 
GIP- AUC were not correlated with HIC. Glucagon- AUC 
was negatively correlated with HIC, but there were no 
significant differences between the high and low HIC 
groups. Adiponectin was positively correlated with HIC. The 
ZnT8 gene polymorphism did not affect HIC.
Conclusions These results suggest that HIC was 
increased in patients with high HbA1c type 2 diabetes, 
low insulin secretion, low insulin resistance and high 
adiponectin conditions.
InTRoduCTIon
The pathophysiology of type 2 diabetes is 
decreased insulin secretion and insulin resis-
tance in various tissues.1 Hepatic insulin 
clearance (HIC) is a new and important patho-
physiology of hyperinsulinemia, metabolic 
syndrome and type 2 diabetes.2 Some studies 
reported that HIC was decreased in patients 
with type 2 diabetes.3 However, this study 
was performed in subjects with an impaired 
glucose tolerance level, and it is not known 
whether poorly controlled diabetes increases 
HIC in patients with type 2 diabetes.
Another study suggested that hypergly-
cemia enhances HIC.4 This study showed 
that the humans with the solute carrier family 
30- member 8 (SLC30A8) risk allele and zinc 
transporter-8 (ZnT8) knockout mice have 
increased HIC, which was assessed using the 
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C- peptide- to- insulin ratio, and postprandial hypergly-
cemia.4 The SLC30A8 gene is a disease susceptibility gene 
in patients with type 2 diabetes.5 SLC30A8 encodes ZnT8, 
which delivers zinc ions from the cytoplasm into insulin 
granules.6 These results suggested that the SLC30A8 
gene is important for HIC. ZnT8 expression is downregu-
lated in the early stage of diabetes in mice.7 These results 
suggest that many patients with diabetes with hypergly-
cemia have dysregulated insulin clearance.
Moreover, another study reported that glucagon- like 
peptide-1 (GLP-1) protects HIC in mice,8 but it is not 
known whether GLP-1 protects HIC in patients with 
poorly controlled type 2 diabetes.
We investigated whether HIC was increased in patients 
with poorly controlled diabetes, and evaluated whether 
HIC was associated with insulin resistance using the 
glucose clamp test. We also analyzed postprandial GLP-1, 
glucose- dependent insulinotropic polypeptide (GIP), 




Twenty- one patients with type 2 diabetes participated in 
this study at Tottori University Hospital between 2013 
and 2017. Type 2 diabetes was diagnosed using the WHO 
criteria.9 Patients with pancreatic disease, viral hepatitis, 
liver cirrhosis, renal failure or those taking diabetogenic 
medications such as corticosteroids were excluded from 
this study. All participants were on diet therapy alone, 
and all were of Japanese ethnicity. This study had a cross- 
sectional design. The sample size was planned to be 
over 20 subjects, and the subjects were divided into the 
following two groups with 10 subjects in each group: high 
or low HIC.
Meal tolerance test
The participants attended our hospital after fasting over-
night for at least 12 hours. The participants ate a test 
meal that was devised by the Japan Diabetes Society (460 
kcal/1882 kJ; 50% carbohydrate, 15% protein, 35% fat 
and 1.6 g salt).10 We measured plasma glucose, serum 
insulin and serum C- peptide at 0, 30, 60 and 120 min 
after the test meal. We measured plasma glucose using 
the glucose oxidase method, and serum insulin and 
C- peptide levels using chemiluminescent immunoas-
says (human insulin and C- peptide chemiluminescent 
immunoassay kits; Kyowa Medix, Tokyo, Japan). We 
measured HbA1c using high- performance liquid chro-
matography. In accordance with the Japanese Clinical 
Practice Guidelines for Diabetes that were created by 
Japan Diabetes Society, we considered HbA1c >8% to 
represent poor glycemic control.11 We converted HbA1c 
percentage values into the International Federation of 
Clinical Chemistry values (mmol/mol) using the HbA1c 
converter from the National Institutes of Diabetes and 
Digestive and Kidney Diseases.12
Insulin resistance was calculated as follows: homeo-
static model assessment insulin resistance (HOMA- 
IR)13=[fasting plasma glucose (FPG) (mmol/L)]×[fasting 
plasma insulin (pmol/L)]/135.
HOMA of beta cell function (HOMA- beta)={20×[fasting 
plasma insulin (pmol/L)]}/{[FPG (mmol/L)]−3.5}.13
HOMA- IR did not show a normal distribution, so we 
also calculated log HOMA- IR.
Insulinogenic index={[insulin (pmol/L) at 30 min]−
[insulin (pmol/L) at 0 min]}/{[glucose (mmol/L) at 
30 min]−[glucose (mmol/L) at 0 min]}.14
HIC was calculated as follows: ratio of the incremental 
areas under the meal tolerance test (MTT) curve (area 
under the curve (AUC)) C- peptide 0–120 min/AUC 
insulin 0–120 min).14 The AUC was calculated using the 
trapezoidal method.
Early phase C- peptide secretion was calculated from 
the C- peptide- AUC0–30 (AUC C- peptide 0–30 min).15–17 
We also calculated C- peptide- AUC0–120 (AUC C- peptide 
0–120 min).
An ELISA kit was used to measure plasma adiponectin 
levels (human adiponectin ELISA kit, 410614, Otsuka, 
Tokyo, Japan).
GlP-1, GIP and glucagon assays
The serum samples were obtained using a blood collec-
tion tube containing dipeptidyl peptidase-4 inhibitor 
(BD P800, BD Japan, Tokyo, Japan). Ethanol and solid- 
phase extractions were performed,18 and intact GLP-1 
levels were measured using a GLP-1 (active) ELISA 
(Catalog Number EGLP- 35K; Merck Millipore, Darm-
stadt, Germany). The active GIP was measured using 
the Human GIP, Active form Assay Kit (Catalog Number 
27201, IBL, Gunma, Japan). Glucagon levels were 
measured using a glucagon ELISA (Catalog Number 
10-1271-01 Mercodia, Uppsala, Sweden).
Hyperinsulinemic–euglycemic clamp
We performed the glucose clamp test as previously 
reported.19 Briefly, the hyperinsulinemic–euglycemic 
clamp was performed using an artificial endocrine 
pancreas (STG 55; Nikkiso, Shizuoka, Japan) to eval-
uate insulin sensitivity. We used the protocol involving a 
primed constant infusion of insulin (100 mU/m2/min) 
and maintained the plasma glucose levels at 5.2 mmol/L 
(95 mg/dL). Based on previous studies, this method 
achieved a steady- state plasma insulin level of 1200 pmol/L 
in patients with type 2 diabetes.20 The steady- state glucose 
infusion rate (GIR) from 90 to 120 min was measured; 
the mean GIR during this time was defined as the glucose 
disposal rate (GDR), which is used as a marker of periph-
eral insulin sensitivity. We also calculated the M/I ratio 
as a measure of the quantity of glucose metabolized per 
unit of plasma insulin concentration, and we defined the 
M value as the GDR and the I value as the steady state 
insulin concentration.21 For convenience of data expres-
sion, we multiplied the M/I ratio by 1200.
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Table 1 Participant characteristics
Parameters Parameters
n 21 Duration of diabetes (years) 3.8±4.6
Sex (male/female) 10/11 eGFR (mL/min/1.73 m2) 85.3±22.4
Age (years) 56.5±10.8 Creatinine (mg/dL) 0.78±0.22
BMI (kg/m2) 27.3±4.4 LDL- C (mmol/L) 3.30±0.78
Waist circumstance (cm) 94.5±13.6 HDL- C (mmol/L) 1.16±0.30
Fasting plasma glucose (mmol/L) 7.1±1.1 TG (mmol/L) 1.60±0.76
HbA1c (%) 7.6±0.8 HOMA- beta (%) 70.4±40.2
HbA1c (mmol/mol) 59.6±8.7 HOMA- IR 4.0±2.6
AST (IU/L) 33.0±17.8 Log HOMA- IR 0.5±0.4
ALT (IU/L) 51.0±34.2 GDR (mg/kg/min) 5.6±1.9
Gamma- GTP (IU/L) 54.1±50.1 M/I 6.6±6.4
Fasting insulin (pmol/L) 74.5±46.6 Adiponectin (μg/mL) 5.1±2.4
Fasting C- peptide (nmol/L) 0.8±0.3 Fasting GLP-1 (pmol/L) 1.4±0.4
HIC 7.7±3.4 Fasting GIP (pmol/L) 3.1±2.4
C- peptide- AUC0–30 1.6±0.7 Fasting glucagon (pmol/L) 77.5±52.9
C- peptede- AUC0–120 3.2±1.3   
Data are presented as the mean±SD.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve; BMI, body mass index; eGFR, estimated 
glomerular filtration rate; GDR, glucose disposal rate; GIP, glucose- dependent insulinotropic polypeptide; GLP-1, glucagon- like peptide-1; 
GTP, glutamyl transpeptidase; HbA1c, glycated hemoglobin; HDL- C, high- density lipoprotein cholesterol; HIC, hepatic insulin clearance; 
HOMA- beta, homeostatic model assessment beta cell function; HOMA- IR, homeostasis model assessment for insulin resistance; LDL, low- 
density lipoprotein cholesterol.
Zn34 gene analysis
The SLC30A8 risk allele, rs13266634, was assessed using 
the PCR single- strand conformation polymorphism 
method after DNA sequencing.22 We divided the patients 
into non- risk allele (T/C and T/T, n=13) and risk allele 
(C/C, n=8) groups.4
Genomic DNA was obtained from peripheral blood 
leukocytes using proteinase K digestion and phenol/chlo-
roform extraction. The PCR mixture contained genomic 
DNA as a template, each primer, dNTPs, AmpliTaq 
Gold (PE Biosystems, Tokyo, Japan) and supplemented 
buffer. PCR was performed under the following condi-
tions: 5 min at 95°C and then amplification for 35 cycles 
of 1 min at 95°C, 1 min at 60°C and 1 min at 72°C in a 
thermal cycler. The products were separated on 2% 
agarose gel to confirm their size.
dna sequencing
A direct sequence reaction was performed using an ABI 
PRISM BigDye Terminator Cycle Sequencing Kit, and the 
sequencing samples were analyzed using an ABI PRISM 
310 Genetic Analyzer (PE Biosystems). Sequence data 
were analyzed using the software package ALF (Phar-
macia, Tokyo, Japan) and GENETYXMAC software (Soft-
ware Development, Tokyo, Japan).
statistical analysis
Data are expressed as the mean±SD. We determined 
correlations between parametric clinical variables and 
HIC using Spearman’s correlation analysis. We defined 
the threshold of high or low HIC as the median HIC 
value. We conducted a power analysis to compare the low 
HIC and high HIC groups using an EZR calculator.23 We 
assessed differences in the mean value of clinical param-
eters between high HIC and low HIC participants using 
the Mann- Whitney U test. The χ2 test was used for cate-
gorical comparisons of sex data.
Values of p<0.05 were considered to be statistically 
significant. SPSS software V.26.0 (SPSS, Chicago, Illinois, 
USA) was used for all analyses.
ResulTs
Participant characteristics are shown in table 1. The 
mean HIC was 7.7±3.4.
The MTT results are shown in figure 1. The HIC was 
significantly correlated with HbA1c (r_S=0.58, p<0.01; 
table 2).
The BMI was also correlated with HIC. Age, FPG, 
postprandial glucose (PPG) 2 hours, aspartate amino-
transferase and alanine aminotransferase were not 
correlated with HIC, but gamma- GTP was correlated 
with HIC. HOMA- beta was significantly correlated with 
HIC (r_S=−0.77, p<0.01), and the insulinogenic index 
was correlated with HIC (r_S=−0.70, p<0.001). C- pep-
tide- AUC0–30 and C- peptide- AUC0–120 were correlated 
with HIC (r_S=−0.49, p<0.05; r_S=−0.52, p<0.05, respec-
tively). HOMA- IR was correlated with HIC (r_S =−0.66, 
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Figure 1 The meal tolerance test (MTT) results. (A) Glucose levels after the MTT, (B) insulin, (C) C- peptide, (D) glucagon- like 
peptide-1 (GLP-1), (E) glucose- dependent insulinotropic polypeptide (GIP) and (F) glucagon. Black circles represent the data for 
all subjects, white triangles indicate low hepatic insulin clearance (HIC) subjects, and white squares indicate high HIC subjects.
p<0.005). Log HOMA- IR showed an equal correlation 
compared with HOMA- IR. The GDR was not correlated 
with HIC in the clamp study (r_S=0.27, p=0.23), but the 
M/I value was significantly correlated with HIC (r_S=0.46, 
p<0.05). GLP-1- AUC and GIP- AUC were not correlated 
with HIC, but glucagon- AUC was correlated with HIC. 
Adiponectin was significantly correlated with HIC.
The overall median HIC value was 6.5. The mean 
HIC in the low HIC group was 5.20±1.05, and the mean 
HIC in the high HIC group was 10.75±3.35. The differ-
ence between the mean HIC in the low and high HIC 
groups was 5.75±2.29. We conducted a power analysis 
of the statistical test that was used to compare the low 
and high HIC groups. Assuming that the difference in 
 on S
eptem











are: first published as 10.1136/bm





5BMJ Open Diab Res Care 2020;8:e001149. doi:10.1136/bmjdrc-2019-001149
Pathophysiology/Complications
Table 2 Correlation coefficients between the hepatic 





BMI (kg/m2) −0.51 <0.05
Duration of diabetes −0.01 N.S.
Fasting plasma glucose 0.04 N.S.
Postprandial plasma glucose 2 hours 0.17 N.S.
AST −0.31 N.S.
ALT −0.29 N.S.
Gamma- GTP −0.61 <0.005
HbA1c 0.58 <0.01
HOMA- beta −0.77 <0.01
Insulinogenic Index −0.70 <0.001
C- peptide- AUC0–30 −0.49 <0.05
C- peptede- AUC0–120 −0.52 <0.05
HOMA- IR −0.66 <0.005




GLP-1 AUC 0.20 N.S.
GIP AUC −0.17 N.S.
Glucagon AUC −0.67 <0.005
Correlation coefficients were determined using Spearman’s 
product moment correlation coefficient test.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
AUC, area under the curve; BMI, body mass index; GDR, glucose 
disposal rate; GIP, glucose- dependent insulinotropic polypeptide; 
GLP-1, glucagon- like peptide-1; GTP, glutamyl transpeptidase; 
HbA1c, glycated hemoglobin; HOMA- beta, homeostatic model 
assessment beta cell function; HOMA- IR, homeostasis model 
assessment for insulin resistance; N.S., not significant.
the means was 5.75 and the SD was 2.29, the estimated 
power was >99.9%. In patients with a high HIC above 
the median, the mean HbA1c was significantly higher 
compared with patients with a low HIC below the median 
(8.10% vs 7.10%, p<0.01; table 3).
The mean BMI, gamma- GTP, HOMA- beta, insulino-
genic index, C- peptide- AUC0–30, C- peptide- AUC0–120 
and HOMA- IR in the low HIC group were significantly 
higher, and the M/I value and adiponectin were signifi-
cantly lower, compared with those of the high HIC group 
(table 3). The mean PPG in low HIC group was nearly 
significantly lower compared with that of high HIC group 
(p=0.06). The mean glucagon AUC in low HIC group 
was also nearly significantly higher compared with that 
of high HIC group (p=0.09). There was no significant 
sex and duration difference between high and low HIC 
groups.
Seven subjects had a drinking habit, and 14 subjects 
did not have a drinking habit. We compared the mean 
gamma- GTP level of each group, and there was no signif-
icant difference between each group. However, the non- 
drinker group had higher gamma- GTP levels compared 
with the drinker group (drinker 42.6±24.2 vs non- drinker 
60.3±59.6, p=0.42).
There were three subjects with the SLC30A8 risk allele 
in the low HIC group and three of these subjects in the 
high HIC group. There was no significant difference in 
the mean HIC between the SLC30A8, rs13266634 risk 
group and the low- risk group (8.24 vs 8.15, p=0.96).
dIsCussIon
This study showed that HIC was increased in patients 
with high HbA1c type 2 diabetes, especially in patients 
with HbA1c >8%. The HIC was significantly correlated 
with HbA1c. The mean HbA1c of the high HIC group 
was significantly higher compared with that of the low 
HIC group below the median. Previous studies reported 
that HIC was decreased in patients with type 2 diabetes 
and metabolic syndrome. However, the glucose levels 
in these studies were mild, with fasting plasma glucose 
levels of 4.9±0.1 mmol/L2 and 5.3±0.5 mmol/L.3 HIC 
was shown to increase in animals with hyperglycemia, 
and insulin becomes unstable in the hyperglycemic 
condition because the zinc ion is important for insulin 
crystal; however, zinc ion regulation is disturbed in the 
hyperglycemic condition.4 These results suggest that 
HIC is decreased in patients with mild hyperglycemia, 
but HIC was increased in patients with severe hypergly-
cemia. Therefore, postprandial insulin levels in patients 
with poorly controlled type 2 diabetes should be inter-
preted with caution. We suggest that postprandial C- pep-
tide levels should be measured in patients with poorly 
controlled type 2 diabetes to determine their ability to 
secrete insulin. However, there are no other clinical 
results or animal study results in the poorly controlled 
diabetes condition. Further research is required.
The insulin secretion index HOMA- beta and the insu-
linogenic index are significantly correlated with HIC. We 
also analyzed C- peptide- based insulin secretion ability 
because the insulin- based insulin secretion index is 
affected by insulin clearance. C- peptide- AUC0–30 and 
C- peptide- AUC0–120 were also significantly correlated 
with HIC. These correlations were weaker compared 
with HOMA- beta and the insulinogenic index. However, 
these results suggested that insulin secretion is important 
for insulin clearance. Because insulin use is a saturable 
process, the higher HIC values may result from reduced 
insulinemia rather than from a mechanism that is 
related to stronger glucose intolerance. Figure 1 shows 
that during the MTT, insulin is much higher in the 
low clearance group. Thus, the lower clearance may be 
strongly related to saturation mechanisms, rather than 
to homeostasis mechanisms. Further studies including 
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Table 3 Comparison between low and high hepatic insulin clearance
Parameters
HIC <6.5 HIC >6.5
P value(n=10) (n=11)
Age (years) 58.3±11.0 60.2±10.6 N.S.
Sex (male/female) 4/6 6/5 N.S.
BMI (kg/m2) 29.9±2.76 24.1±4.3 <0.001
Duration of diabetes (years) 2.8±4.6 4.6±4.6 N.S.
Fasting plasma glucose (mmol/L) 7.12±0.57 7.18±1.44 N.S.
Postprandial plasma glucose 2 hours (mmol/L) 9.68±2.10 11.45±2.08 0.06
AST (U/L) 39.6±23.0 25.3±6.7 N.S.
ALT (U/L) 63.0±44.1 36.6±15.6 N.S.
Gamma- GTP (U/L) 77.2±62.6 30.0±13.0 0.01
HbA1c (%) 7.10±0.75 8.10±0.53 <0.001
HOMA- beta (%) 102.6±23.3 35.7±24.0 <0.001
Insulinogenic Index 1.09±1.22 0.24±0.11 <0.001
C- peptide- AUC0–30 1.98±0.69 1.16±0.33 <0.005
C- peptede- AUC0–120 4.02±1.32 2.43±0.57 <0.005
HOMA- IR 5.89±1.77 2.17±1.89 <0.005
GDR (mg/kg/min) 5.19±1.91 6.22±2.10 N.S.
M/I 4.34±1.89 10.09±9.15 <0.05
Adiponectin (μg/mL) 3.92±3.43 6.75±8.45 <0.05
GLP-1 AUC 6.99±2.83 8.91±4.81 N.S.
GIP AUC 109.70±39.53 102.30±43.99 N.S.
Glucagon AUC 225.76±103.56 123.26±104.75 0.09
Data are presented as the mean±SD.
The comparison of parameters between low and high hepatic insulin clearance was performed using the Mann- Whitney U test. The χ2 test 
was used for categorical comparisons of the sex data.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve; BMI, body mass index; GDR, glucose disposal 
rate; GIP, glucose- dependent insulinotropic polypeptide; GLP-1, glucagon- like peptide-1; GTP, glutamyl transpeptidase; HbA1c, glycated 
hemoglobin; HIC, hepatic insulin clearance; HOMA- beta, homeostatic model assessment beta cell function; HOMA- IR, homeostasis model 
assessment for insulin resistance; N.S., not significant.
investigation of the insulin secretion ability, such as using 
the hyperglycemic clamp, are required.
In this study, gamma- GTP in the low HIC group was 
significantly higher compared with the high HIC group. 
A similar result was reported by a previous study, where 
increased gamma- GTP and ALT were observed in healthy 
individuals with a high hepatic insulin resistance and 
decreased HIC.24 We compared the mean gamma- GTP 
level in the alcohol drinker and non- drinker groups, 
and while there was no significant differences between 
the groups, the non- drinker group showed a higher 
gamma- GTP level. We suspect that this means that a 
drinking habit did not have a large influence in this 
study. Moreover, HOMA- IR was strongly correlated with 
HIC, and the M/I value was associated with HIC, but the 
GDR was not associated with HIC. HOMA- IR is mainly 
associated with hepatic insulin resistance, and GDR is 
mainly associated with muscle insulin resistance.25 There-
fore, these results suggest that hepatic insulin resistance 
is associated more with HIC than with muscle insulin 
resistance.
The previous report also showed a positive correla-
tion between ALT and fasting glucagon levels in type 2 
diabetes.24 In our study, the glucagon AUC was signifi-
cantly and negatively correlated with HIC. Another study 
reported that postmenopausal white women had lower 
glucagon concentrations and higher HIC compared with 
black women.26 These results suggest that glucagon levels 
are associated with HIC and hepatic insulin resistance. 
However, there were no significant differences in the 
glucagon AUC between the high and low HIC groups in 
our study. Further studies are required.
One study reported that a cannabinoid receptor 1 antag-
onist increases HIC in fat- fed dogs, which likely occurred 
via upregulation of liver adiponectin receptors.27 In our 
study, adiponectin was significantly correlated with HIC. 
These results suggest that adiponectin is associated with 
HIC.
Another study reported that injection of GLP-1 reduces 
endogenous insulin clearance in mice, and thus, it may 
affect insulin levels by increasing prehepatic insulin 
secretion and reducing insulin clearance.8 However, the 
 on S
eptem











are: first published as 10.1136/bm





7BMJ Open Diab Res Care 2020;8:e001149. doi:10.1136/bmjdrc-2019-001149
Pathophysiology/Complications
AUC of postprandial GLP-1 was not correlated with HIC 
in our study. These results suggest that the GLP-1 physi-
ological range may not affect the HIC, but high GLP-1 
levels reduce the HIC. However, another study reported 
that a reduction in HIC after oral glucose ingestion is not 
mediated by GLP-1 or by GIP in humans.28 The effects 
of GLP-1 on HIC may be different between humans and 
mice. This article and our results suggested that the effect 
of GLP-1 on HIC is not as strong in humans. Further 
studies are required to determine the effects of GLP-1 
administration on HIC.
There was also no significant difference in the mean 
HIC between the SLC30A8 high- risk and low- risk groups. 
This suggests that HIC is associated more with hypergly-
cemia than with the patient’s genetic background.
Our study had several limitations. The relatively small 
number of participants indicates that our results require 
confirmation with a larger study. Therefore, we added 
‘A Preliminary Report’ to the title. Because we recruited 
patients with diabetes who had no previous insulin inter-
vention, it is possible that we failed to recruit subjects 
with low insulin sensitivity who had decreased insulin 
secretion. However, the glucose clamp test is a compli-
cated technique, and it is difficult to recruit patients with 
poorly controlled diabetes who are not taking medica-
tion. We are currently conducting a larger study, and we 
will publish the results in the future. Because hepatic 
clearance exists independently from the test that is used 
to quantify it, there are differences between consuming 
a test meal and administering a pure glucose load, 
which also affects glucose and insulin levels. The MTT 
was used in our study because it is best to avoid OGTTs 
in patients with severe diabetes because of the risk of 
hyperglycemia. However, some studies used the HIC that 
was obtained from MTT, we consider that our study was 
acceptable.26 Although we would like to investigate HIC, 
data about insulin clearance using a glucose clamp are 
also important.29 Unfortunately, we did not measure the 
C- peptide levels at steady state during the glucose clamp 
in this study. However, it is possible that the ratio of AUCs 
for C- peptide and insulin reflects the endogenous clear-
ance rather than hepatic clearance. Figure 1 and another 
article show that 120 min is a very short time interval in 
which to use AUCs, considering the very different kinetics 
of insulin and C- peptide because the dynamics of both 
variables at 120 min is mostly incomplete.30 We would like 
to investigate insulin clearance using the glucose clamp 
data in a future study. We also excluded patients with 
serum creatinine >1.3 mg/dL based on an earlier report, 
because C- peptide levels are strongly affected by renal 
function.31 Care must be taken when calculating the HIC 
using C- peptide in patients with renal insufficiency. We 
also did not evaluate hepatic insulin resistance, because 
we cannot use tritium- glucose in Japan. Despite these 
limitations, we believe that our study contributes to our 
daily clinical work.
In conclusion, these results suggested that HIC was 
increased in patients with high HbA1c type 2 diabetes, 
low insulin secretion, low insulin resistance and high 
adiponectin conditions.
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